Profile: Enterologics Inc (ELGO.PK)

ELGO.PK on OTC Markets Group

27 Jun 2014
Price Change (% chg)

$-0.00 (-14.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Enterologics, Inc., incorporated on September 2, 2009, is a biotechnology company engaged in the development of live biotherapeutic products for gastrointestinal disorders. The Company focuses to license or acquire technology to build a product pipeline based on producing probiotic bacteria in shelf-stable, formulations that are delivered orally. On September 6, 2011, the Company acquired BioBalance Corp. (BioBalance) and BioBalance LLC from New York Health Care, Inc. (NYHC). The Company acquired a probiotic product, E. coli M17.

E. coli M17 has an Investigational New Drug application (IND) with the Food & Drug Administration (United States) (FDA) for the indication of maintenance of symptomatic remission in chronic antibiotic-dependent pouchitis. As of December 31, 2011, the Company has not generated any revenues.

Company Address

Enterologics Inc

Suite 404, 1246 University Ave W
ST. PAUL   MN   55104
P: +1516.3038181
F: +1516.7060027

Search Stocks